MECP2 and pancreatic neoplasm: Furthermore, it was found that MeCP2, as a coactivator, enhanced Smad3 binding to the furin promoter to activate Furin/ TGF-β1/Smad signaling resulting in the promotion of EMT in pancreatic cancer cells.